Increased plasma concentrations of tumour markers in the absence of neoplasia

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 10, 2011, Pages 1605-1620

  Trapé, Jaume ^a   Filella, Xavier ^b   Alsina Donadeu, Montse ^c   Juan Pereira, Lluïsa ^d   Bosch Ferrer, Àngels ^e   Rigo Bonnin, Raül ^f  

^a Althaia   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Clinical Analysis Laboratory   (Spain)

^d University of Barcelona   (Spain)

^e Consorci Laboratori Intercomarcal ^*  (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

benign disease; false positives; tumour markers

Indexed keywords

ALPHA FETOPROTEIN; BETA 2 MICROGLOBULIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CHROMOGRANIN A; COBALAMIN; CREATININE; CYTOKERATIN 19 FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; HETEROPHILE ANTIBODY; LACTATE DEHYDROGENASE; NEURON SPECIFIC ENOLASE; OMEPRAZOLE; PROGASTRIN RELEASING PEPTIDE; PROSTATE SPECIFIC ANTIGEN; PROTEIN S 100; SQUAMOUS CELL CARCINOMA ANTIGEN; THYROGLOBULIN; TUMOR MARKER;

ACUTE LIVER FAILURE; ACUTE PANCREATITIS; ANTIGEN EXPRESSION; ATRESIA; BLOOD LEVEL; BRONCHIECTASIS; CANCER INFILTRATION; CHOLECYSTITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; CROHN DISEASE; EFFUSION; FALSE POSITIVE RESULT; FIBROSING ALVEOLITIS; FLUID RETENTION; GASTRITIS; GASTROINTESTINAL DISEASE; GRAVES DISEASE; HEMODIALYSIS; HEMOLYSIS; HEPATITIS; HEPATOBILIARY DISEASE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER DISEASE; LIVER FUNCTION TEST; LIVER NECROSIS; LOW DRUG DOSE; LUNG TUBERCULOSIS; LYMPHOCYTE ACTIVATION; MENSTRUAL CYCLE; MESOTHELIUM; MUELLERIAN DUCT; MYOSITIS; NEOPLASM; OBSTRUCTIVE JAUNDICE; OVARY DISEASE; PATHOPHYSIOLOGY; PEPTIC ULCER; PERICARDIAL EFFUSION; PREGNANCY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PSEUDOCYST; REVIEW; SYSTEMIC SCLEROSIS; THYROID ADENOMA; THYROIDITIS; TISSUE DISTRIBUTION;

FALSE POSITIVE REACTIONS; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 80054963506     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.694     Document Type: Review

References (205)

1. Ballesta AM, Molina R. Tumor markers: Definition and classification. In: Ballesta AM, Torre GC, Bombardieri E, Gion M, Molina R, editors. Updating on tumor markers in tissues and in biological fluids. Turí: Edizioni Minerva Medica; 1993.
2. Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem 2002;48:1151-9. (Pubitemid 34809819)
3. Murohisa T, Sugaya H, Tetsuka I, Suzuki T, Harada T. A case of common bile duct stone with cholangitis presenting an extraordinarily high serum CA19-9 value. Intern Med 1992;31: 516-20.
4. Filella X, Cases A, Molina R, Jo J, Bedini JL, Revert L, et al. Tumor markers in patients with chronic renal failure. Int J Biol Markers 1990;5:85-8. (Pubitemid 20380258)
5. Symeonidis A, Kouraklis-Symeonidis A, Apostolopoulos D, Arvanitopoulou E, Giannakoulas N, Vassilakos P, et al. Increased serum CA-15.3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency. Oncology 2004;67: 359-67.
6. Bredow MT, Goldie DJ. Rapid falls in maternal serum alphafetoprotein concentrations. Clin Pathol 1985;38:473-4. (Pubitemid 15106616)
7. Mizejewski GJ, Bellisario R, Beblowski DW, Carter TP. Commercial radioimmunoassay kit for measurement of alpha-fetoprotein adapted for use with dried blood specimens from newborns. Clin Chem 1982;28:1207-10. (Pubitemid 12116699)
8. Schneider DT, Calaminus G. Diagnostic value of alpha1-fetoprotein and beta-human chorionic gonadotropin in infancy and childhood. Pediatr Hemat Oncol 2001;18:11-26. (Pubitemid 32064223)
9. Bellini C, Bonacci W, Paridu E, Serra G. Serum alpha-fetoprotein in newborns. Clin Chem 1998;44:2548-50.
10. Trapé J, Botargues JM, Porta F, Ricós C, Badal JM, Salinas R, et al. Reference change value for alpha-fetoprotein and its application in early detection of hepatocellular carcinoma in patients with hepatic disease. Clin Chem 2003;49:1209-11. (Pubitemid 36751118)
11. Schiødt FV, Ostapowicz G, Murray N, Satyanarana R, Zaman A, Munoz S, et al. Alpha-fetoprotein and prognosis in acute liver failure. Liver Transpl 2006;12:1776-81. (Pubitemid 44911803)
12. Eleftheriou N, Heathcote J, Thomas HC, Sherlock S. Serum alpha-fetoprotein levels in patients with acute and chronic liver disease. Relation to hepatocellular regeneration and development of primary liver cell carcinoma. J Clin Pathol 1977;30: 704-8. (Pubitemid 8192059)
13. Arrieta O, Cacho B, Morales-Espinosa D, Ruelas-Villavicencio A, Flores-Estrada D, Hernández-Pedro N. The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. BMC Cancer 2007;7:28.
14. Katz VL, Cefalo RC, McCune BK, Moos MK. Elevated second trimester maternal serum alpha-fetoprotein and cytomegalovirus infection. Obstet Gynecol 1986;68:580-1. (Pubitemid 16014517)
15. Andres JM, Lilly JR, Altman RP, Walker WA, Alpert E. Alpha1-fetoprotein in neonatal hepatobiliary disease. J Pediatr 1977;91:217-21.
16. Grem JL, Trump DL. Reversible increase in serum alpha-fetoprotein content associated with hepatic dysfunction during chemotherapy for seminoma. J Clin Oncol 1986;4:41-5. (Pubitemid 16155960)
17. Germà JR, Llanos M, Tabernero JM, Mora J. False elevations of alpha-fetoprotein associated with liver dysfunction in germ cell tumors. Cancer 1993;72:2491-4. (Pubitemid 23299616)
18. Phaneuf D, Lambert M, Laframboise R, Mitchell G, Lettre F, Tanguay RM. Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient. J Clin Invest 1992;90:1185-92.
19. Blesa JR, Giner-Duran R, Vidal J, Lacalle ML, Catalán I, Bixquert M, et al. Report of hereditary persistence of alpha-fetoprotein in a Spanish family: Molecular basis and clinical concerns. J Hepatol 2003;38:541-4. (Pubitemid 36399262)
20. Alj Y, Georgiakaki M, Savouret JF, Mal F, Attali P, Pelletier G, et al. Hereditary persistence of alpha-fetoprotein is due to both proximal and distal hepatocyte nuclear factor-1 site mutations. Gastroenterology 2004;127:308-17. (Pubitemid 38040745)
21. Huang KY, Shyur SD, Wang CY, Shen EY, Liang DC. Ataxia telangiectasia: Report of two cases. J Microbiol Immunol Infect 2001;34:71-5.
22. Dursun P, Ersoz S, Gultekin M, Aksan G, Yüce K, Ayham A. Disseminated peritoneal tuberculosis mimicking advanced stage endodermal sinus tumor: A case report. J Gynecol Cancer 2006;(Suppl 1):303-7.
23. Petri M, Ho AC, Patel J, Demers D, Joseph JM, Goldman D. Elevation of maternal alpha-fetoprotein in systemic lupus erythematosus: A controlled study. J Rheumatol 1995;22:1365-8.
24. Trapé J, Molina R, Sant F. Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions. Tumour Biol 2004;25:276-81. (Pubitemid 40082331)
25. Molina R, Filella X, Bruix J, Mengual PJ, Bosch X, Calvet X, et al. Cancer Antigen125 in serum and ascitic fluid of patients with liver disease. Clin Chem 1991;37:1379-83. (Pubitemid 21925975)
26. Takahashi N, Shimada T, Ishibashi Y, Oyake N, Murakami Y. Transient elevation of serum tumor markers in a patient with hypothyroidism. Am J Med Sci 2007;333:387-9. (Pubitemid 46945482)
27. Nagata H, Takahashi K, Yamane Y, Yoshino K, Shibukawa T, Kitao M. Abnormally high values of CA 125 and CA 19-9 in women with benign tumors. Gynecol Obstet Invest 1989;28: 165-8. (Pubitemid 19254302)
28. Renaud MC, Plante M, Roy M. Ovarian thecoma associated with a large quantity of ascites and elevated serum CA 125 and CA 15-3. J Obstet Gynaecol Can 2002;24:963-5.
29. Faggiano P, D'Aloia A, Brentana L, Bignotti T, Fiorina C, Vizzardi E, et al. Serum levels of different tumour markers in patients with chronic heart failure. Eur J Heart Fail 2005;7: 57-61. (Pubitemid 40092492)
30. Núñez J, Núñez E, Consuegra L, Sanchis J, Bodí V, Martínez-Brotons A, et al. Carbohydrate antigen 125: An emerging prognostic risk factor in acute heart failure? Heart 2007;93:716-21. (Pubitemid 46808274)
31. Bon GG, Kenemans P, Dekker JJ, Hompes PG, Verstraeten RA, van Kamp GJ. Schoemaker Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles. J Hum Reprod 1999;14:566-70. (Pubitemid 29097419)
32. Talbot RW, Jacobsen DJ, Nagorney DM, Malkasian GD, Ritts RE Jr. Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer. Surg Gynecol Obstet 1989;168:407-12. (Pubitemid 19147691)
33. Marechal F, Berthiot G, Deltour G. Serum levels of CA 50, CA 19-9, CA 125, CA 15-3, Enolase and carcino-embryonic anti gen in non neoplastic diseases of the lung. Anticancer Res 1988;8:677-80.
34. Ozsahin SL, Turgut B, Nur N, Dogan OT, Erselcan T, Berk S. Validity of the CA125 level in the differential diagnosis of pulmonary tuberculosis. Jpn J Infect Dis 2008;61:68-9. (Pubitemid 351338534)
35. Klug TL, Green PJ, Zurawski VR, Davis HM. Confirmation of a false-positive result in CA 125 immunoradiometric assay caused by human anti-idiotypic immunoglobulin. Clin Chem 1998;34:1071-6.
36. Amoura Z, Duhaut P, Huong DL, Wechsler B, Costedoat-Chalumeau N, Francès C, et al. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev 2005;14:1279-82.
37. Collazos J, Genollá J, Ruibal A. CA 15.3 in non-malignant liver diseases. Int J Biol Markers 1991;6:188-92.
38. Collazos J, Genolla J, Ruibal A. Breast cancer-associated antigen CA 15.3 in liver cirrhosis. Acta Oncol 1992;31:741-4. (Pubitemid 23050609)
39. Wong RC, Klingberg S, Wilson R. CA15-3 and cancer associated serum antigen assays are alternatives to the KL-6 assay for measuring serum MUC-1 levels in patients with interstitial lung disease associated with polymyositis/dermatomyositis. J Rheumatol 2002;29:2021-2. (Pubitemid 34988719)
40. Briasoulis E, Andreopoulou E, Tolis CF, Bairaktari E, Katsaraki A, Dimopoulos MA, et al. G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting. Cancer 2001;91:909-17.
41. Szekanecz E, Szucs G, Szekanecz Z, Tarr T, Antal-Szalmás P, Szamosi S, et al. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: Associations with organ manifestations, immunolaboratory markers and disease activity indices. J Autoimmun 2008;31:372-6.
42. Cherchi PL, Capobianco G, Ambrosini G, Fadda GM, Piga MD, Ruiu G, et al. Intracystic evaluation of tumor markers in benign and malignant ovarian pathology. Eur J Gynaecol Oncol 2002;23:163-5. (Pubitemid 34297124)
43. Xiaofang Y, Yue Z, Xialian X, Zhibin Y. Serum tumour markers in patients with chronic kidney disease. Scand J Clin Lab Invest 2007;67:661-7. (Pubitemid 351411736)
44. Molina R, Gion M, Gressner A, Troalen F, Auge JM, Holdenrieder S, et al. Alternative antibody for the detection of CA15-3 antigen: A European multicenter study for the evaluation of the analytical and clinical performance of the Access BR Monitor assay on the UniCel Dxl 800 Immunoassay System. Clin Chem Lab Med 2008;46:612-22. (Pubitemid 351749114)
45. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, et al. Radioimmunoassay for a monoclonal-defined tumor marker, CA 19.9. Clin Chem 1983;29:549-52.
46. Duraker N, Hot S, Polat Y, Höbek A, Gençler N, Urhan N. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 2007;95:142-7. (Pubitemid 46238983)
47. Peterli R, Meyer-Wyss B, Herzog U, Tondelli P. CA19-9 has no value as a tumor marker in obstructive jaundice. Schweiz Med Wochenschr 1999;129:77-9. (Pubitemid 29052846)
48. Sakamoto K, Haga Y, Yoshimura R, Egami H, Yokoyama Y, Akagi M. Comparative effectiveness of the tumor diagnostics, CA 19.9, CA 125 and carcinoembryonic antigen in patients with diseases of digestive tract. Gut 1987;28:323-9. (Pubitemid 17039054)
49. Klapdor U, Klapdor R, Helferich G, Striefler D, Bahlo M, Botzow HG, et al. CA 19.9 and CA 125 in the course of acute and chronic non-malignant disease of the gastrointestinal tract. In: Greten H, Klapdor R, editors. New tumour associated antigens. Sttutgart: Georg Thieme Verlag; 1985:60-8.
50. Barone D, Onetto M, Conio M, Paganuzzi M, Saccomanno S, Aste H, et al. CA 19.9 assay in patients with extrahepatic cholestatic jaundice. Int J Biol Markers 1988;3:95-100.
51. Akdogan M, Saşmaz N, Kayhan B, Biyikoglu I, Dişibeyaz S, Sahin B. Extraordinarily elevated CA19-9 in benign conditions: A case report and review of the literature. Tumori 2001;87: 337-9. (Pubitemid 33116917)
52. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA 19-9 in acute cholangitis. Dig Dis Sci 1988;33:1223-5.
53. Piantino P, Fusaro A, Randone A, Cerchier A, Daziano E. Increased levels of Ca 19-9, Ca 50 and Ca 125 in patients with benign diseases of the biliary tract and the pancreas. J Nucl Med Allied Sci 1990;34(4 Suppl):97-102.
54. Petit JM, Vaillant G, Olsson NO, Guignier F, Collignon S, Verges B, et al. Elevated serum CA19.9 levels in poorly controlled diabetic patients. Relationship with Lewis blood group. Gastroenterol Clin Biol 1994;18:17-20. (Pubitemid 24077461)
55. Buccheri GF, Ferrigno D, Sartoris AM, Violante B, Vola F, Curcio A. Tumor markers in bronchogenic carcinoma. Cancer 1987;60:42-50.
56. Vendimian M, Lafitte JJ, Wattre P. Le CA 19.9 dans les cancers primitifs des bronches. Comparison avec l'antigène carcino-embryonnaire. Biomed Pharmacother 1987;41:191-5. (Pubitemid 17105183)
57. Takayama S, Kataoka N, Usui Y, Inase N, Natori Y, Nakayama M, et al. CA 19-9 in patients with benign pulmonary diseases. Nihon Kyobu Shikkan Gakkai Zasshi 1990;28:1326-31.
58. Sumi Y, Ohno K, Yamasaki Y, Hatanaka N, Yamamoto S, Kuwata K. Mediastinal bronchogenic cyst associated with high serum level of CA 19-9-a surgical case report. Jpn J Thorac Cardiovasc Surg 1998;46:110-4.
59. Yigitbasi R, Karabicak I, Aydogan F, Erturk S, Bican O, Aydin O, et al. Benign splenic epithelial cyst accompanied by elevated Ca 19-9 level: A case report. Mt Sinai J Med 2006;73:871-3. (Pubitemid 44768624)
60. Yuksel BC, Ozel H, Akin T, Avsar FM, Hengirmen S. Primary hydatid cyst of the breast with elevated CA 19-9 level. Am J Trop Med Hyg 2005:73:368-70. (Pubitemid 41278715)
61. Harada T, Kubota T, Aso T. Usefulness of CA19.9 versus CA125 for the diagnosis of endometriosis. Fertil Steril 2002;78: 733-9.
62. Moulinier L, Beljio K, Beljio K, Duffaut M, Laroche M, Bon E, et al. Increase of CA 19-9 in dysimmune inflammatory rheumatism. A propose of 6 cases. Rev Rhum Ed Fr 1994;61: 599-606.
63. Howaizi M, Abboura M, Krespine C, Sbai-Idrissi MS, Marty O, Djabbari-Sobhani M. A new cause for CA 19.9 elevation: Heavy tea consumption. Gut 2003;52:913-4. (Pubitemid 36613506)
64. Stieber P, Molina R, Gion M, Gressner A, Troalen F, Holdenrieder S, et al. Alternative antibody for the detection of CA19-9 antigen: A European multicenter study for the evaluation of the analytical and clinical performance of the Access GI Monitor assay on the UniCel Dxl 800 Immunoassay System. Lin Chem Lab Med 2008;46:600-11. (Pubitemid 351749108)
65. Tekin O. Hypothyroidism-related CA 19-9 elevation. Mayo Clin Proc 2002;77:398.
66. Filella X, Molina R, Jo J, Bedini JL, Joseph J, Ballesta AM. Tumor associated glycoprotein (TAG-72) levels in patients with non-malignant and malignant disease. Bull Cancer 1992;79: 271-7.
67. Filella X, Friese S, Roth HJ, Nussbaum S, Wehnl B. Technical performance of the Elecsys CA 72-4 test-development and field study. Anticancer Res 2000;20:5229-32. (Pubitemid 32319112)
68. Halm U, Rohde N, Klapdor R, Reith HB, Thiede A, Etzrodt G, et al. Improved sensitivity of fuzzy logic based tumor marker profiles for diagnosis of pancreatic carcinoma versus benign pancreatic disease. Anticancer Res 2000;20:4957-60. (Pubitemid 32319058)
69. Balaban YH, Simsek H, Yilmaz R, Sarer-Yurekli BP, Shorbagi A, Tatar G. Tumor markers in familial Mediterranean fever and their correlation with the frequency of attacks. Clin Exp Rheumatol 2008;26(4 Suppl 50):114-6.
70. Trapé J, Guiteres P, Roca JM, Montesinos J, Franquesa J. Increased tumor markers concentrations in patients treated with ibuprofen. Tumor Biol 2010;31(Suppl 1):S80.
71. Leung TK, Lee CM, Wang FC, Chen HC, Wang HJ. Difficulty with diagnosis of malignant pancreatic neoplasms coexisting with chronic pancreatitis. World J Gastroenterol 2005;11: 5075-8.
72. Rule AH, Goleski-Reilly C, Sachar DB, Vandevoorde J, Janowitz HD. Circulating carcinoembryonic antigen (CEA): Relationship to clinical status of patients with inflammatory bowel disease. Gut 1973;14:880-4.
73. Weber TH, Kerttula Y. Carcinoembryonic antigen (CEA) in blood in cases of pneumonia. Scand J Infect Dis 1986;18: 547-50. (Pubitemid 17197951)
74. Bédos JP, Hignette C, Lucet JC, Kilani B, Casalino E, Wolff M, et al. Serum carcinoembryonic antigen: A prognostic marker in HIV-related Pneumocystis carinii pneumonia. Scand J Infect Dis 1992;24:309-15.
75. Sekiya M, Chiba A, Ienaga H, Ueki J, Hasunuma K, Takahashi H, et al. Intralobar pulmonary sequestration presenting increased serum CEA, CA 19-9, and CA 125, and associated with asymptomatic pulmonary aspergillosis. Nihon Kokyuki Gakkai Zasshi 1999;37:433-7.
76. Sekiya K, Sakai T, Homma S, Tojima H. Pulmonary tuberculosis accompanied by a transient increase in serum carcinoembryonic antigen level with tuberculous empyema drainage. Intern Med 2007;46:1795-8. (Pubitemid 350131032)
77. Marechal F, Berthiot G, Deltour G. Serum levels of CA-50, CA-19.9, CA-125, CA-15.3, enolase and carcino-embryonic antigen in non neoplastic diseases of the lung. Anticancer Res 1988;8:677-80.
78. George PK, Loewenstein MS, O'Brien MJ, Bronstein B, Koff RS, Zamcheck N. Circulating CEA levels in patients with fulminant hepatitis. Dig Dis Sci 1982;27:139-42. (Pubitemid 12162218)
79. Nakeeb A, Lipsett PA, Lillemoe KD, Fox-Talbot MK, Coleman J, Cameron JL, et al. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am J Surg 1996;171: 147-52; discussion 152-3. (Pubitemid 126349889)
80. Collazos J, Genollà J, Ruibal A. Evaluation of the behavior of carcinoembryonic antigen in cirrhotic patients. Int J Biol Markers 1992;7:244-8. (Pubitemid 23038760)
81. Roman LD, Muderspach LI, Burnett AF, Morrow CP. Carcinoembryonic antigen in women with isolated pelvic masses. Clinical utility? J Reprod Med 1998;43:403-7. (Pubitemid 28244003)
82. Amino N, Kuro R, Yabu Y, Takai SI, Kawashima M, Morimoto S, et al. Elevated levels of circulating carcinoembryonic antigen in hypothyroidism. J Clin Endocrinol Metab 1981;52:457-62. (Pubitemid 11136556)
83. Shapiro M, Scapa E. Elevated carcinoembryonic antigen (CEA) levels in a patient with no malignancy. Hepatogastroenterology 2000;47:163-4. (Pubitemid 30085406)
84. Nakayama M, Satoh H, Ishikawa H, Fujiwara M, Kamma H, Ohtsuka M, et al. Cytokeratin 19 fragment in patients with non-malignant respiratory diseases. Chest 2003;123:2001-6. (Pubitemid 36706725)
85. Fujita J, Ohtsuki Y, Bandoh S, Takashima H, Ueda Y, Wu F, et al. Elevation of cytokeratin 19 fragment (CYFRA 21-1) in serum of patients with radiation pneumonitis: Possible marker of epithelial cell damage. Respir Med 2004;98:294-300. (Pubitemid 38443688)
86. Tramonti G, Ferdeghini M, Donadio C, Norpoth M, Annichiarico C, Bianchi R, et al. Renal function and serum concentration of five tumor markers (TATI, SCC, CIFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia. Cancer Detect Prev 2000;24:86-90. (Pubitemid 30152744)
87. Nakahama H, Tanaka Y, Fujita Y, Fujii M, Sugita M. CYFRA 21-1 and ProGRP, tumor markers of lung cancer, are elevated in chronic renal failure patients. Respirology 1998;3:207-10. (Pubitemid 28509179)
88. Kashiwabara K, Kishi K, Nakamura H, Yagyu H, Kobayashi K, Watanabe O, et al. Mechanism of increased serum cytokeratin 19 fragment levels in patients with diabetic nephropathy as a model of chronic renal failure. Intern Med 1998;37:917-21. (Pubitemid 128520909)
89. Romero S, Fernández C, Arriero JM, Espasa A, Candela A, Martín C, et al. CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J 1996;9:17-23. (Pubitemid 26038814)
90. Molina R, Agusti C, Filella X, Jo J, Joseph J, Giménez N, et al. Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. Tumour Biol 1994;15:318-25. (Pubitemid 24369415)
91. Molina R, Filella X, Torres MD, Ballesta AM, Mengual P, Cases A, et al. SCC antigen measured in malignant and non-malignant diseases. Clin Chem 1990;36:251-4.
92. Savary L. Squamous cell carcinoma antigen: Levels in various groups. Tumor markers in the management of squamous cell carcinoma of the neck and the lung. Amsterdam: Excerpta Medica 1987:11-9.
93. Ballesta AM. Squamous cell carcinoma antigen: Levels in various groups. Tumor markers in the management of squamous cell carcinoma of the head, neck and lung. Amsterdam: Excerpta Medica 1987:11-9.
94. Suzuki K, Suzuki T, Akiyama J, Takashima Y, Yamada T, Kawashima M, et al. Serum and pleural SCC-antigen levels in patients with pulmonary tuberculosis. Kekkaku 1993;68: 551-7. (Pubitemid 23341891)
95. Ferrer J, Villarino MA, Encabo G, Felip E, Bermejo B, Vilà S, et al. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer 1999;86:488-95.
96. Upham J, Campbell B. Utility of squamous cell carcinoma antigen (SCC Ag) as a tumor marker in pulmonary malignancy. Respir Med 1992;86:201-3.
97. Campbell B, De'Ambrosis B. Squamous cell carcinoma antigen in patients with cutaneous disorders. J Am Acad Dermatol 1990;22:639-42. (Pubitemid 20134706)
98. Tsukahara T, Otoyama K, Horiuchi Y. Significance of elevated serum squamous cell carcinoma (SCC)-related antigen and lactate dehydrogenase (LDH) levels in senile erythroderma following eczema. J Dermatol 1993;20:346-50. (Pubitemid 23268372)
99. El-Rachkidy RG, Young HS, Griffiths CE, Camp RD. Humoral autoimmune responses to the squamous cell carcinoma antigen protein family in psoriasis. J Invest Dermatol 2008;128: 2219-24.
100. Yamane Y, Moriyama K, Yasuda C, Miyata S, Aihara M, Ikezawa Z, et al. New horny layer marker proteins for evaluating skin condition in atopic dermatitis. Int Arch Allergy Immunol 2009;150:89-101.
101. Kashiwabara K, Nakamura H, Yagyu H, Kishi K, Matsuoka T, Esaki T. Changes in squamous cell carcinoma-related antigen levels before and after hemodialysis in relation to the model of dialyzer employed. Intern Med 2000;39:291-5.
102. Tramonti G, Ferdeghini M, Donadio C, Norpoth M, Annichiarico C, Bianchi R, et al. Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia. Cancer Detect Prev 2000;24:86-90. (Pubitemid 30152744)
103. Kato H, Torigoe T. Human cervical squamous cell carcinoma. Cancer 1977;40:1621-8.
104. Torre GC. Squamous cell carcinoma antigen: Levels in various groups. Tumor markers in the management of squamous cell carcinoma of the cervix and vagina. Amsterdam: Excerpta Medica 1987;7-15.
105. Gocze PM, Vahrson HW, Freeman DA. Serum levels of squamous cell carcinoma antigen and ovarian carcinoma antigen (ca 125) in patients with benign and malignant diseases of the uterine cervix. Oncology 1994;51:430-4. (Pubitemid 24255308)
106. Maruo T, Shibata K, Kimura A, Hoshina M, Mochizuki M. Tumor-associated antigen TA-4 in the monitoring of the effects of therapy for squamous cell carcinoma of the uterine cervix. Cancer 1985;56:302-8. (Pubitemid 15031651)
107. Senekjian EK, Young JM, Weiser PA, Spencer CE, Magic SE, Herbst AL. An evaluation of squamous cell carcinoma antigen in patients with cervical squamous cell carcinoma. Am J Obstet Gynecol 1987;157:433-9.
108. Collazos J, Rodriguez J. Squamous cell carcinoma antigen in patients with cirrhosis. Clin Chem 1993;39:548. (Pubitemid 23099031)
109. Gris JM, Xercavins J, Trillo L, Encabo G. Estudio del antí-geno del carcinoma de células escamosas (SCC) en las enfermedades benignas. Med Clin 1996;6:205-8. (Pubitemid 126565237)
110. Giannelli G, Marinosci F, Trerotoli P, Volpe A, Quaranta M, Dentico P, et al. SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC. Int J Cancer 2005;117: 506-9. (Pubitemid 41429576)
111. Biasiolo A, Chemello L, Quarta S, Cavalletto L, Bortolotti F, Caberlotto C, et al. Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis. J Viral Hepat 2008;15:246-9. (Pubitemid 351326902)
112. Neal DE Jr, Clejan S, Sarma D, Moon TD. Prostate specific antigen and prostatitis I: Effect of prostatitis on serum PSA in the human and nonhuman primate. Prostate 1992;20:105-11.
113. Tchetgen MB, Oesterling JE. The effect of prostatitis urinary retention, ejaculation, and ambulation on the serum prostatespecific antigen concentration. Urologic Clinics North Am 1997;24:283-91. (Pubitemid 27169252)
114. Ambruster DA. Prostate-specific antigen: Biochemistry, analytical methods, and clinical application. Clin Chem 1993;39: 181-95.
115. Filella X, Molina R, Jo J, Umbert B, Bedini JL, Ballesta AM. Clinical usefulness of prostate specific antigen and prostatic acid phosphatase in patients with prostatic cancer. Tumor Biol 1990;11:289-94. (Pubitemid 20376828)
116. Klein LT, Lowe FC. The effects of prostatic manipulation on prostate-specific antigen levels. Urol Clin North America 1997;24:293-7. (Pubitemid 27169253)
117. Yuan JJ, Coplen DE, Petros JA, Figenshau RS, Ratliff TL, Smith DS, et al. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol 1992;147:810-4.
118. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, et al., National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for the use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79. (Pubitemid 352777353)
119. Douville P, Tiberi M. Effect of terminal renal failure on the ratio of free to total prostate-specific antigen. Tumor Biol 1998;19:113-7.
120. Horinaga M, Kitamura K, Saito S, Ukimura O, Nakanoma T, Okihara K, et al. Prostate cancer screening with prostate-specific antigen in hemodialysis patients. Urol Int 2007;78: 334-7. (Pubitemid 46725705)
121. Tzanakis I, Kazoulis S, Girousis N, Kagia S, Spandidakis V, Karefillakis N, et al. Prostate-specific antigen in hemodialysis patients and the influence of dialysis in its levels. Nephron 2002;90:230-3. (Pubitemid 34702005)
122. Djavan B, Kazoulis S, Girousis N, Kagia S, Spandidakis V, Karefillakis N, et al. Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: Is prostate cancer detection compromised in patients receiving long-term dialysis? Urology 1999;53:1169-74. (Pubitemid 29264748)
123. Yu H, Diamandis EP, Zarghami N, Grass L. Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat 1994;32: 291-300. (Pubitemid 24351376)
124. Diamandis EP, Yu H, Sutherland DJ. Detection of prostatespecific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 1994;32:301-10. (Pubitemid 24351377)
125. Yu H, Diamandis EP, Sutherland DJ. Immunoreactive prostate-specific antigen levels in females and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994;27:75-9. (Pubitemid 24146156)
126. Yu H, Diamandis EP. Prostate-specific antigen in milk of lactating women. Clin Chem 1995;41:54-8.
127. Yu H, Diamandis EP. Prostate-specific antigen immunoreactivity in amniotic fluid. Clin Chem 1995;41:204-10.
128. Yu H, Diamandis EP. Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique. J Urol 1995;153:1004-8.
129. Filella X, Molina R, Alcover J, Casals E, Carmona F, Ballesta AM. Prostate specific antigen in non-serum samples from women. Int J Biol Markers 1995;10:238-9.
130. Filella X, Molina R, Alcover J, Menéndez V, Giménez N, Jo J, et al. Prostate-specific antigen detection ultrasensitive assay in samples from women. Prostate 1996;29:311-6. (Pubitemid 26372604)
131. Levesque M, Yu H, D'Costa M, Diamandis EP. Prostate-specific antigen expression by various tumors. J Clin Lab Anal 1995;9:123-8.
132. Pummer K, Wirnsberger G, Pürstner P, Stettner H, Wandschneider G. False positive prostate specific antigen values in the sera of women with renal cell carcinoma. J Urol 1992; 148:21-3.
133. Djavan B, Keffer JH, Molberg K, Roehrborn CG. False-positive serum prostate-specific antigen values in a patient with non-Hodgkin lymphoma of the kidney. Urology 1995;45: 875-8.
134. Pezzilli R, Bertaccini A, Billi P, Zanarini L, Miglio F, Martorana G. Serum prostate-specific antigen in pancreatic disease. Ital J Gastroenterol Hepatol 1999;31:580-3. (Pubitemid 29527845)
135. Bosch X, Bernadich O. Increased serum prostate-specific antigen in a man and a woman with hepatitis A. N Engl J Med 1997;337:1849-50.
136. Malavaud B, Miédougé M, Payen JL, Izopet J, Rischmann P, Pascal JP, et al. Prostate-specific antigen in acute hepatitis and hepatocellular carcinoma. Prostate 1999;41:258-62.
137. Kilic S, Güntekín E, Danişman A, Kukul E, Süleymanlar I, Sevük M. Serum free and total prostate-specific antigen levels in patients with liver disease. Urology 1998;52:825-7.
138. Braren V, Goddard J, Brill AB, Touya JJ. Beta-2-microglobulin as renal diagnostic agent. Urology 1979;13:624-8. (Pubitemid 9204881)
139. Piscator M. Serum beta2-microglobulin in cadmium exposed workers. Pathol Biol 1978;26:321-3. (Pubitemid 9070130)
140. Bardeguez AD, Connor E, Stephens R, Denny TN, Holland B, Oleske J. Effect of human immunodeficiency virus infection on serum beta2-microglobulin levels in pregnant women. Obstet Gynecol 1999;94:537-42. (Pubitemid 29460936)
141. Alarcon A, Garcia-Alix A, Cabañas F, Hernanz A, Pascual-Salcedo D, Martin-Ancel A, et al. Beta-2-microglobulin concentrations in cerebrospinal fluid correlate with neuroimaging findings in newborns with symptomatic congenital cytomegalovirus infection. Eur J Pediatr 2006;165:636-45. (Pubitemid 44134225)
142. Matos AC, Durao MS Jr, Pacheco-Silva A. Serial beta-2-microglobulin measurement as an auxiliary method in the early diagnosis of cytomegalovirus infection in renal transplant patients. Transplant Proc 2004;36:894-5. (Pubitemid 38766213)
143. Elefsiniotis IS, Scarmeas N, Glynou I, Pantazis KD, Kada H, Mavrogiannis C. Serum beta2-microglobulin levels in hepatitis B antigen-negative chronic hepatitis B patients under long term lamivudine monotherapy: Relationship with virological breakthrough. Can J Gastroenterol 2004;18:307-13. (Pubitemid 38801785)
144. Akdogan M, Senturk H, Mert A, Tabak F, Ozbay G. Acute exacerbation interferon alfa treatment of chronic hepatitis B: Frequency and relation to serum beta-2-microglobulin levels. J Gastroenterol 2003;38:465-70. (Pubitemid 36701581)
145. Collazos J, Martínez E, Mayo J. Evolution of serum beta2-microglobulin concentrations during treatment of tuberculosis patients. Scand J Infect Dis 1999;31:265-7. (Pubitemid 29389234)
146. Scagnolari C, Bellomi F, Trombetti S, Casato M, Carlesimo M, Bagnato F, et al. Expression of biomarkers of interferon type I in patients suffering from chronic diseases. Clin Exp Immunol 2007;147:270-6. (Pubitemid 46096005)
147. Hoermann R, Spoett G, Moncayo R, Mann K. Evidence for the presence of human chorionic gonadotropin (hCG) and free b-subunit of hCG in the human pituitary. J Clin Endocrinol Metab 1990;71:179-86.
148. Buckner CL, Wilson L, Christine N. Papadea. Case report: An unusual cause of elevated serum total bhCG. Ann Clin Lab Sci 2007;37:186-91. (Pubitemid 46717199)
149. Cole LA. Khanlian SA. Inappropriate management of women with persistent low hCG results. J Reprod Med 2004;49: 423-32. (Pubitemid 38781416)
150. Rotmensch S, Cole LA. False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations. Lancet 2000; 355:712-5.
151. Schwarz A, Post KG, Keller F, Molzahn M. Value of human chorionic gonadotropin measurements in blood as pregnancy test in women on maintenance hemodialysis. Nephron 1985; 39:341-3. (Pubitemid 15131296)
152. Bucker CL, Wilson L, Papadea CN. An unusual cause of elevated serum total beta hCG. Ann Clin Lab Sci 2007;37: 186-91. (Pubitemid 46717199)
153. Palmieri C, Dhillon T, Fisher TA, Young AM, Short D, Mitchell H, et al. Management and outcome of healthy women with a persistently elevated b-hCG. Gynecol Oncol 2007;106:35-43. (Pubitemid 46898568)
154. Cheng PJ, Chu DC, Chueh HY, See LC, Chang HC, Weng DR. Elevated maternal midtrimester serum free beta-human chorionic gonadotropin levels in vegetarian pregnancies that cause increased false-positive Down syndrome screening results. Am J Obstet Gynecol 2004;190:442-7. (Pubitemid 38249242)
155. Moncayo R, Moncayo HE. A new endocrinological and immunological syndrome in SLE: Elevation of human chorionic gonadotropin and of antibodies directed against ovary and endometrion antigens. Lupus 1995;4:39-45.
156. Hematology and Medical Oncology. Marijuana can raise a man's bHCG. In: Stoller JK, Michota FA, Mandell BF, editors. The Cleveland Clinic Intensive Review of Internal Medicine. Philadelphia: Lippincott Williams & Wilkins; 2005:335.
157. Kim T, Loh YP. Chromogranin A: A surprising link between granule biogenesis and hypertension. J Clin Invest 2003; 115:1711-3.
158. Kimura N, Hoshi S, Takahashi M, Takeha S, Shizawa S, Nagura H. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. J Urol 1997;157:565-8. (Pubitemid 27026839)
159. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H. Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002;167:512-5. (Pubitemid 34074517)
160. Ranno S, Motta M, Rampello E, Risino C, Bennati E, Malaguarnera M. The chromogranin-A (CgA) in prostate cancer. Arch Gerontol Geriatr 2006;43:117-26. (Pubitemid 43866964)
161. Spadaro A, Ajello A, Morace C, Zirilli A, D'arrigo G, Luigiano C, et al. Serum chromogranin-A in hepatocellular carcinoma: Diagnostic utility and limits. World J Gastroenterol 2005;11:1987-90. (Pubitemid 40520997)
162. Massironi S, Fraquelli M, Paggi S, Sangiovanni A, Conte D, Sciola V, et al. Chromogranin A levels in chronic liver disease and hepatocellular carcinoma. Dig Liver Dis 2009;41:31-5.
163. Larsen AI, Helle KB, Christensen M, Kvaløy JT, Aarsland T, Dickstein K. Effect of exercise training on chromogranin A and relationship to N-ANP and inflammatory cytokines in patients with chronic heart failure. Int J Cardiol 2008;23; 127:117-20. (Pubitemid 351707511)
164. Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart 2009;95:1508-13.
165. Jansson AM, Røsjø H, Omland T, Karlsson T, Hartford M, Flyvbjerg A, et al. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J 2009;30:25-32.
166. Estensen ME, Hognestad A, Syversen U, Squire I, Ng L, Kjekshus J, et al. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J 2006;152:927.e1-6.
167. Sobol RE, O'Connor DT, Addison J, Suchocki K, Royston I, Deftos LJ. Elevated serum chromogranin A concentrations in small-cell lung carcinoma. Ann Intern Med 1986;105:698-700. (Pubitemid 17176974)
168. Sørhaug S, Langhammer A, Waldum HL, Hveem K, Steinshamn S. Increased serum levels of chromogranin A in male smokers with airway obstruction. Eur Respir J 2006;28: 542-8. (Pubitemid 44794668)
169. Ziegler MG, Kennedy B, Morrissey E, O'Connor DT. Norepinephrine clearance, chromogranin A and dopamine beta hydroxylase in renal failure. Kidney Int 1990;37:1357-62. (Pubitemid 20148562)
170. Kurnatowska I, Nowicki M. Serum chromogranin A concentration and intradialytic hypotension in chronic haemodialysis patients. Int Urol Nephrol 2006;38:701-5. (Pubitemid 46336028)
171. Tsao KC, Hong JH, Wu TL, Chang PY, Sun CF, Wu JT. Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis. J Clin Lab Anal 2007;21:193-6. (Pubitemid 46808914)
172. Al-Shoumer KA, Vasanthy BA. Serum chromogranin A concentration in hyperthyroidism before and after medical treatment. J Clin Endocrinol Metab 2009;94:2321-4.
173. Peracchi M, Gebbia C, Basilisco G, Quatrini M, Tarantino C, Vescarelli C, et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol 2005;152:443-8. (Pubitemid 40439498)
174. Sciola V, Massironi S, Conte D, Caprioli F, Ferrero S, Ciafardini C, et al. Plasma chromogranin A in patients with inflammatory bowel disease. Inflamm Bowel Dis 2009;15: 867-71.
175. Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996;39:649-53. (Pubitemid 26426463)
176. Giusti M, Sidoti M, Augeri C, Rabitti C, Minuto F. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 2004;150:299-303. (Pubitemid 38443779)
177. Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, et al. Serum gastrin and chromogranin A during medium-and long-term acid suppressive therapy: A case-control study. Aliment Pharm Therap 1999;13:145-53. (Pubitemid 29090008)
178. Esscher T, Steinholtz L, Bergh J, Nöu E, Nilsson K, Pahlman S. Neurone specific enolase: A useful diagnostic serum marker for small cell carcinoma of the lung. Thorax 1985;40:85-90. (Pubitemid 15114112)
179. Muley T, Ebert W, Stieber P, Raith H, Holdenrieder S, Nagel D, et al. Technical performance and diagnostic utility of the new Elecsys neuron-specific enolase enzyme immunoassay. Clin Chem Lab Med 2003;41:95-103. (Pubitemid 36285392)
180. Collazos J, Esteban C, Fernández A, Genollá J. Measurement of the serum tumor marker neuron-specific enolase in patients with benign pulmonary diseases. Am J Respir Crit Care Med 1994;150:143-5. (Pubitemid 24209950)
181. Vos PE, Lamers KJ, Hendriks JC, van Haaren M, Beems T, Zimmerman C, et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 2004;62:1303-10. (Pubitemid 38526041)
182. Jauch EC, Lindsell C, Broderick J, Fagan SC, Tilley BC, Levine SR. NINDS rt-PA Stroke Study Group. Association of serial biochemical markers with acute ischemic stroke: The National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke 2006;37:2508-13. (Pubitemid 44454670)
183. Strachan MW, Abraha HD, Sherwood RA, Lammie GA, Deary IJ, Ewing FM, et al. Evaluation of serum markers of neuronal damage following severe hypoglycaemia in adults with insulin-treated diabetes mellitus. Diabetes Metab Res Rev 1999;15:5-12. (Pubitemid 29257808)
184. Collazos J, Genollá J, Ruibal A. Neuron-specific enolase concentrations in serum in benign liver diseases. Clin Chem 1991;37:579-81. (Pubitemid 21892698)
185. Massabki PS, Silva NP, Lourenço DM, Andrade LE. Neuron specific enolase concentration is increased in serum and decreased in platelets of patients with active systemic sclerosis. J Rheumatol 2003;30:2606-12. (Pubitemid 37549337)
186. Sugano K, Kawai T, Ishii M, Koyama H, Kitajima M, Kasumi F, et al. Clinical study of serum ErbB-2 protein using sandwich radioimmunometric assay (ErbB-2 IRMA 'Eiken'). Gan To Kagaku Ryoho 1994;21:1245-53. (Pubitemid 24248045)
187. Molina R, Jo J, Filella X, Bruix J, Castells A, Hague M, et al. Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumour Biol 1997;18: 188-6.
188. Motoo Y, Sawabu N, Yamaguchi Y, Mouri I, Yamakawa O, Watanabe H, et al. Serum levels of c-erbB-2 protein in digestive diseases. J Gastroenterol 1994;29:616-20. (Pubitemid 24308412)
189. Molina R, Auge JM, Alicarte J, Filella X, Viñolas N, Ballesta AM. Pro-gastrin-releasing peptide in patients with benign and malignant diseases. Tumour Biol 2004;25:56-61. (Pubitemid 38822772)
190. Molina R, Navarro J, Filella X, Castel T, Ballesta AM. S-100 protein serum levels in patients with benign and malignant diseases: False-positive results related to liver and renal function. Tumour Biol 2002;23:39-44. (Pubitemid 34225020)
191. Undén J, Christensson B, Bellner J, Alling C, Romner B. Serum S100B levels in patients with cerebral and extracerebral infectious disease. Scand J Infect Dis 2004;36:10-3. (Pubitemid 38219764)
192. Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H. GFAP versus S100B in serum after traumatic brain injury: Relationship to brain damage and outcome. J Neurotrauma 2004;21:1553-61. (Pubitemid 39525165)
193. Reynolds MA, Kirchick HJ, Dahlen JR, Anderberg JM, McPherson PH, Nakamura KK, et al. Early biomarkers of stroke. Clin Chem 2003;49:1733-9. (Pubitemid 37194242)
194. Yang XY, Lin J, Lu XY, Zhao XY. Expression of S100B protein levels in serum and cerebrospinal fluid with different forms of neuropsychiatric systemic lupus erythematosus. Clin Rheumatol 2008;27:353-7.
195. Pacini F, Lari R, La Ricca P, Grasso L, Taddei D, Bardini N, et al. Serum thyroglobulin in newborns' cord blood, in childhood and adolescence: A physiological indicator of thyroidal status. J Endocrinol Invest 1984;7:467-71. (Pubitemid 15177804)
196. Van Herle AJ, Uller RP, Matthews NL. Radioimmunoassay for measurement of thyroglobulin in human serum. J Clin Invest 1973;52:1320-7.
197. Van Herle AJ, Vassart G, Dumont JE. Control of thyroglobulin synthesis and secretion. N Engl J Med 1979;301:307-14.
198. Shimaoka K, van Herle AJ, Dindogru A. Thyrotoxicosis secondary to involvement of the thyroid with malignant lymphoma. J Clin Endocrinol Metab 1976;43:64-8.
199. Schneider AB, Parvos R. Radioimmunoassay of human thyroglobulin effect of antithyroglobulin autoantibodies. J Clin Endocrinol Metab 1978;47:126-32.
200. Mariotti S, Cupini C, Giani C, Pinchera A. Evaluation of a solid phase immunoradiometric assay for serum thyroglobulin: Effect of anti-thyroglobulin autoantibody. Clin Chim Acta 1982;123:347-52.
201. Pacini F, Elisei R, Taddei D, Pinchera A. Clinical validation of immunoradiometric assay for measuring serum thyroglobulin in antithyroglobulin autoantibody positive sera in patirets with thyroid cancer. In: Cimino F, Birkmayer GD, Klavins JV, Pimentel E, Salvatore F, editors. Human tumor markers. Berlin: Walter de Gruyter, 1987;695-7.
202. British Thyroid Association. Guidelines for the management of thyroid cancer in adults. London: Royal College of Physicians, 2007. http://www.british-thyroid-association.org/guidelines.
203. Rotmensch S, Cole LA. False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations. Lancet 2000; 355:712-5.
204. Esfandiari N, Goldberg JM. Heterofile antibody blocking agent to confirm false positive serum human chorionic gonadotropin assay. Obstet Gynecol 2003;101:1144-6. (Pubitemid 36566408)
205. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, et al. National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79. (Pubitemid 352777353)